- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT00550277
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma
A Phase II Study of LBH589 in the Treatment of Patients With Refractory Clear Cell Renal Carcinoma
Studieoversigt
Detaljeret beskrivelse
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
Kontakter og lokationer
Studiesteder
-
-
Florida
-
Fort Myers, Florida, Forenede Stater, 33901
- Florida Cancer Specialists
-
-
Georgia
-
Gainesville, Georgia, Forenede Stater, 30501
- Northeast Georgia Medical Center
-
-
Louisiana
-
Baton Rouge, Louisiana, Forenede Stater, 70806
- Baton Rouge General Medical Center
-
-
Maryland
-
Bethesda, Maryland, Forenede Stater, 20817
- Center for Cancer and Blood Disorders
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Methodist Cancer Center
-
-
New Jersey
-
Morristown, New Jersey, Forenede Stater, 07960
- Hematology Oncology Associates of Northern NJ
-
-
Ohio
-
Cincinnati, Ohio, Forenede Stater, 45242
- Oncology Hematology Care
-
-
Tennessee
-
Chattanooga, Tennessee, Forenede Stater, 37404
- Chattanooga Oncology Hematology Associates
-
Nashville, Tennessee, Forenede Stater, 37023
- Tennessee Oncology, PLLC
-
-
Virginia
-
Newport News, Virginia, Forenede Stater, 23601
- Peninsula Cancer Institute
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Histologically documented metastatic or locally unresectable clear cell renal carcinoma. In patients with mixed histologies, the clear cell component must comprise > 75% of the cancer.
- Documented disease progression or intolerance while receiving treatment with: a) sunitinib, sorafenib, or both, and b) temsirolimus.
- Maximum of 4 prior systemic regimens allowed and may include other targeted agents, immunotherapy and chemotherapy.
- Measurable disease by RECIST criteria.
- ECOG PS 0 or 1.
- Laboratory values as follows: ANC >= 1500/μL, Hgb >= 9 g/dL, Platelets >= 100,000/uL, AST/SGOT and ALT/SGPT <= 2.5 x ULN or <= 5.0 x ULN in patients with liver metastases, Creatinine <= 2.0 mg/dL Or Calculated Creatinine Clearance >= 50 ml/min, Albumin >= 3 g/dL, Potassium >= lower limit normal (LLN),Phosphorous >= LLN, Calcium >= LLN, Magnesium > LLN
- Women of childbearing potential must have a negative serum or urine pregnancy test performed within 7 days prior to start of treatment.
- Life expectancy > 12 weeks.
- Accessible for treatment and follow-up.
- All patients must be able to understand the nature of the study and give written informed consent prior to study entry.
Exclusion Criteria:
- Age < 18 years of age.
- Prior treatment with an HDAC inhibitor.
- Impaired cardiac function
- Ongoing therapy with antiarrhythmics or other medications associated with QTc prolongation.
- Uncorrected hypokalemia or hypomagnesemia.
- Uncontrolled hypertension or cardiac arrhythmias.
- Active parenchymal brain metastases. Patients who have had brain metastases resected, or have received radiation therapy ending > 8 weeks prior to study entry are eligible if they meet all of the following criteria: 1) residual neurologic symptoms < grade 1, 2) no dexamethasone requirement, 3) follow-up MRI shows regression of lesions after treatment, with no new lesions appearing.
- Active meningeal metastases.
- Known diagnosis of human immunodeficiency virus (HIV) infection.
- Unresolved diarrhea > CTCAE grade 1.
- Concomitant requirement for medication classified as CYP3A4 inducers or inhibitors.
- Chemotherapy, investigational drug therapy, major surgery < 4 weeks prior to starting study drug or patients that have not recovered from side effects of previous therapy.
- Patient is < 5 years free of another primary malignancy except if the other primary malignancy is not currently clinically significant or requiring active intervention, or if other primary malignancy is a basal cell skin cancer or a cervical carcinoma in situ. Existence of any other malignant disease is not allowed.
- Concomitant use of any anti-cancer therapy or radiation therapy.
- Pregnant or breast feeding or female of reproductive potential not using 2 effective methods of birth control.
- Male patients whose sexual partners are women of childbearing potential not using effective birth control.
- Patients with gastrointestinal (GI) tract disease, causing the inability to take oral medication, malabsorption syndrome, a requirement for intravenous (IV) alimentation, prior surgical procedures affecting absorption, uncontrolled inflammatory GI disease.
- Other concurrent severe, uncontrolled infection or intercurrent illness
- Abnormal thyroid function (TSH or free T4) detected at screening. Patients with known hypothyroidism who are stable on thyroid replacement are eligible.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Andet: Treatment
LBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly).
To enable patients to undergo cardiac monitoring, all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
Patients with objective response or stable disease after re-evaluation at week 8 will continue LBH589 at the same dose until disease progression, unacceptable toxicity and/or at the discretion of the investigator.
|
LBHLBH589 will be administered orally at a dose of 45 mg (1 - 5 mg capsule and 2 - 20 mg capsules) on Monday and Thursday of each week (twice weekly).
To enable patients to undergo cardiac monitoring (Section 3.5.2),
all patients must begin treatment on a Monday, and continue Monday/Thursday dosing during subsequent treatment cycles.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Progression-free Survival
Tidsramme: 18 months
|
Progression-free survival was defined as the interval from the date of first treatment with panobinostat until the date that disease progression or death occurred.
Progressive disease (PD): 20% increase in the sum of diameters of target measurable lesions above the smallest sum observed (over baseline if no decrease in the sum is observed during therapy), with a minimum absolute increase of 5 mm.
|
18 months
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
---|---|---|
Number of Participants Experiencing ≥Grade 2 Adverse Events
Tidsramme: 18 months
|
An adverse event (AE) is the development of an undesirable medical condition, or the deterioration of a preexisting medical condition (other than the condition that is being treated by the trial) following or during exposure to a pharmaceutical product, whether or not considered causally related to the product.
The number of participants experiencing such adverse events that are related to the study drug are reported here.
|
18 months
|
Number of Participants With Overall Response
Tidsramme: 18 months
|
Response was evaluated in this study using the new international criteria proposed by the Response Evaluation Criteria in Solid Tumors (RECIST) Committee. Overall response is defined as the proportion of participants whose disease either decreased (partial response- PR) or disappeared (Complete response - CR). Complete Response (CR): Disappearance of all target lesions. Partial Response (PR): At least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD |
18 months
|
Samarbejdspartnere og efterforskere
Samarbejdspartnere
Efterforskere
- Studiestol: John D. Hainsworth, M.D., SCRI Development Innovations, LLC
Publikationer og nyttige links
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Neoplasmer efter histologisk type
- Neoplasmer
- Urologiske neoplasmer
- Urogenitale neoplasmer
- Neoplasmer efter sted
- Nyresygdomme
- Urologiske sygdomme
- Adenocarcinom
- Neoplasmer, kirtel og epitel
- Nyre-neoplasmer
- Karcinom, nyrecelle
- Karcinom
- Molekylære mekanismer for farmakologisk virkning
- Enzymhæmmere
- Antineoplastiske midler
- Histon deacetylase hæmmere
- Panobinostat
Andre undersøgelses-id-numre
- SCRI GU 49
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Nyrecellekarcinom
-
Universitaire Ziekenhuizen KU LeuvenUkendtLymfom | Hodgkin lymfom | Non-Hodgkin lymfom (follikulært, diffust B-cel lymfom, PTLD og Mantle Cel lymfom)Belgien
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk Ureter Urothelial Carcinoma | Stadie IV Blære Urothelial Carcinoma AJCC v7 | Metastatisk nyrebækken og Ureter Urothelial CarcinomaForenede Stater
-
Association Pour La Recherche des Thérapeutiques...AfsluttetClear Cell Metastatic Renal Cell CarcinomaFrankrig
-
Universitaire Ziekenhuizen KU LeuvenAfsluttetForekomst af Augmented Renal Clearance | Risikofaktorer for øget renal clearanceBelgien
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Metastatisk Urothelial Carcinom | Lokalt avanceret blæreurothelial karcinom | Lokalt avanceret nyrebækken Urothelial Carcinoma | Lokalt... og andre forholdForenede Stater
-
Medical University of ViennaAfsluttetGlomerulær filtreringshastighed | Fedtsyrer, ikke-esterificerede | Renal Cirkulation | Renal Plasma FlowØstrig
-
The First People's Hospital of ChangzhouIkke rekrutterer endnu
-
Roswell Park Cancer InstituteIovance Biotherapeutics, Inc.Trukket tilbageMetastatisk blæreurothelial karcinom | Metastatisk nyrebækken Urothelial Carcinom | Metastatisk Ureter Urothelial Carcinoma | Metastatisk Urethral Urothelial Carcinoma | Uoperabelt nyrebækken Urothelial Carcinom | Uoperabelt Ureter Urothelial CarcinomaForenede Stater
-
Sunnybrook Health Sciences CentrePfizerAfsluttetClear Cell Metastatic Renal Cell CarcinomaCanada
Kliniske forsøg med LBH589
-
City of Hope Medical CenterNational Cancer Institute (NCI)Afsluttet
-
Sidney Kimmel Cancer Center at Thomas Jefferson...NovartisAfsluttetHjernemetastase | Tilbagevendende gliom | Meningiom af høj kvalitetForenede Stater
-
Mayo ClinicNational Cancer Institute (NCI)AfsluttetEkstranodal marginalzone B-celle lymfom i slimhinde-associeret lymfoidt væv | Nodal Marginal Zone B-celle lymfom | Tilbagevendende voksen Burkitt lymfom | Tilbagevendende voksent diffust storcellet lymfom | Tilbagevendende voksenlymfoblastisk lymfom | Tilbagevendende grad 1 follikulært lymfom | Tilbagevendende... og andre forholdForenede Stater
-
Abdullah KutlarSecura Bio, Inc.RekrutteringSeglcellesygdomForenede Stater
-
Mayo ClinicNational Cancer Institute (NCI)AfsluttetEkstranodal marginalzone B-celle lymfom i slimhinde-associeret lymfoidt væv | Nodal Marginal Zone B-celle lymfom | Tilbagevendende voksen Burkitt lymfom | Tilbagevendende voksent diffust storcellet lymfom | Tilbagevendende voksenlymfoblastisk lymfom | Tilbagevendende grad 1 follikulært lymfom | Tilbagevendende... og andre forholdForenede Stater
-
Anne Beaven, MDNovartisAfsluttetDiffust storcellet B-celle lymfomForenede Stater
-
Novartis PharmaceuticalsAfsluttetMetastatisk brystkræft | HER-2 positiv brystkræftBelgien, Holland, Australien, Italien, Forenede Stater
-
H. Lee Moffitt Cancer Center and Research InstituteNovartis PharmaceuticalsAfsluttetMyelomatoseForenede Stater
-
Novartis PharmaceuticalsAfsluttetMyelomatoseForenede Stater, Tyskland
-
Novartis PharmaceuticalsAfsluttetLymfom | Leukæmi | MyelomatoseForenede Stater, Tyskland, Australien